TNFRSF9 and neoplasm: While none of our immunotherapy approaches (including α-CTLA-4/α-PD-1, α-CD137/α-PD-1, IL-2) possessed any anti-tumor efficacy themselves, only α-CD137/α-PD-1 enhanced the anti-tumor effect of SBRT.